JPH03291232A - Antitumor agent and immunoactivator - Google Patents
Antitumor agent and immunoactivatorInfo
- Publication number
- JPH03291232A JPH03291232A JP2094377A JP9437790A JPH03291232A JP H03291232 A JPH03291232 A JP H03291232A JP 2094377 A JP2094377 A JP 2094377A JP 9437790 A JP9437790 A JP 9437790A JP H03291232 A JPH03291232 A JP H03291232A
- Authority
- JP
- Japan
- Prior art keywords
- reaction
- polysaccharide
- kpb
- acid reaction
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 6
- 150000004676 glycans Chemical class 0.000 claims abstract description 49
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 49
- 239000005017 polysaccharide Substances 0.000 claims abstract description 49
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 8
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 claims abstract description 4
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims abstract description 4
- 238000000921 elemental analysis Methods 0.000 claims abstract description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241000186610 Lactobacillus sp. Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 230000003308 immunostimulating effect Effects 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 229960001438 immunostimulant agent Drugs 0.000 claims description 8
- 239000003022 immunostimulating agent Substances 0.000 claims description 8
- 238000000862 absorption spectrum Methods 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 230000009965 odorless effect Effects 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 230000009967 tasteless effect Effects 0.000 claims description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- XOOMNEFVDUTJPP-UHFFFAOYSA-N naphthalene-1,3-diol Chemical compound C1=CC=CC2=CC(O)=CC(O)=C21 XOOMNEFVDUTJPP-UHFFFAOYSA-N 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract 2
- 230000001988 toxicity Effects 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000007789 gas Substances 0.000 description 10
- 235000015141 kefir Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 229940035901 lactobacillus sp Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- SERLAGPUMNYUCK-URHLDCCQSA-N (2R,3S,4R,5S)-6-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-URHLDCCQSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920001755 Kefiran Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- -1 aptane Chemical compound 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- SRBFZHDQGSBBOR-MBMOQRBOSA-N alpha-D-arabinopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-MBMOQRBOSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- WQMLFJWIKARBFW-BKKMTDGVSA-N evomonoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(CC[C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)O)[C@]3(C)CC1 WQMLFJWIKARBFW-BKKMTDGVSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はラクトバチルスsp、KPB−167を培養し
て得られる多糖を有効成分とする抗腫瘍活性並びに免疫
賦活活性の優れた毒性のない安全な抗腫瘍、免疫賦活剤
に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention provides a non-toxic and safe polysaccharide with excellent anti-tumor activity and immunostimulatory activity, which contains a polysaccharide obtained by culturing Lactobacillus sp, KPB-167 as an active ingredient. Regarding anti-tumor and immunostimulant.
ソ連コーカサス地方の伝統的な発酵乳ケフィールは、ケ
フィール粒と呼ばれるスタータを用いて製造される。こ
のケフィール粒は黄白色の弾力のあるカリフラワー状の
画境であり、各種乳酸菌と酵母萼が共生している。ケフ
ィール粒は、ある種の莢膜性多糖生産性の乳酸菌が作る
多111(ケフィラン)が支持体となって、乳酸菌や酵
母等が接合されて形成されている。このケフィール粒か
ら抽出された多糖には抗腫瘍活性が有ることは開示され
ている(特開昭52−128207号、特公昭56−4
09号。Traditional fermented milk kefir from the Caucasus region of the Soviet Union is produced using a starter called kefir grain. These kefir grains have a yellowish-white elastic cauliflower-like border, and various lactic acid bacteria and yeast calyx coexist. Kefir granules are formed by conjugating lactic acid bacteria, yeast, etc. with poly111 (kefiran) produced by a type of capsular polysaccharide-producing lactic acid bacteria as a support. It has been disclosed that the polysaccharide extracted from this kefir grain has antitumor activity (Japanese Patent Application Laid-Open No. 128207/1983, Japanese Patent Publication No. 56-4
No. 09.
特公昭56−410号公報)。しかしながらケフィール
粒は種々の微生物相で構成されているため、その培養及
び管理が難かしく、また目的とする多糖を生産する莢膜
性多糖生産菌が純粋に分離されていない。従って、どの
ような微生物学的分類に属する菌があるのか不明であり
、上記抗腫瘍活性多糖の物質としての確認はもとより、
安定した同多糖の生産は困難である。Special Publication No. 56-410). However, since kefir grains are composed of various microorganisms, it is difficult to culture and manage them, and the capsular polysaccharide-producing bacteria that produce the desired polysaccharide have not been isolated in a pure manner. Therefore, it is unclear what microbiological classification the bacteria belong to, and it is difficult to confirm that the bacteria is a substance with antitumor activity.
Stable production of this polysaccharide is difficult.
本発明者らは先に、ケフィール粒から莢膜多糖生産菌ラ
クトバチルスsp、KPB−167を分離し、この微生
物が生産する多糖類の生産方法を見出し特願昭63−1
75637号として出願した。The present inventors previously isolated a capsular polysaccharide producing bacterium, Lactobacillus sp, KPB-167, from kefir grains, and discovered a method for producing polysaccharides produced by this microorganism, patent application No. 63-1.
The application was filed as No. 75637.
常に安定した生産性を有し、高品質でしかも抗腫瘍活性
等の活性を有するケフィール粒から抽出された多糖様の
物質の提供は広く要望されている。It is widely desired to provide a polysaccharide-like substance extracted from kefir granules that has consistently stable productivity, high quality, and activities such as antitumor activity.
本発明はこの要望に適合した抗腫瘍、免疫賦活剤を提供
するものである。The present invention provides an antitumor and immunostimulant that meets this need.
本発明者らは上記課題を解決する目的で、本発明者らが
先に発明したケフィール粒から分離したラクトバチルス
sp、KPB−167(微工研菌寄第9886号)を培
養し、その培養液から分離、採取した多糖の抗腫瘍活性
並びに免疫賦活性について研究を行なったところ、この
培養物が極めて高い抗腫瘍、免疫賦活性を有することを
見出し、更にその主成分である多糖を確認し本発明を完
成した。In order to solve the above-mentioned problems, the present inventors cultivated Lactobacillus sp, KPB-167 (Feikoken Bacteria Serial No. 9886), which was isolated from kefir grains that the present inventors had previously invented, and cultivated it. We conducted research on the antitumor activity and immunostimulatory activity of the polysaccharide isolated and collected from the fluid, and found that this culture had extremely high antitumor and immunostimulatory activity.We also confirmed the polysaccharide that is the main component. The invention has been completed.
本発明はラクトバチルスsp、KPB−167(微工研
菌寄第9886%)を培養し、その培養液から分離、採
取された多糖を有効成分とする抗腫瘍、免疫賦活剤並び
に同成分の主要成分が次の理化学的性質を有する多糖で
あることを見出した。The present invention is directed to an antitumor and immunostimulant agent containing a polysaccharide isolated and collected from the culture solution obtained by culturing Lactobacillus sp, KPB-167 (KPB-167 (KPB-167), and the main component of the same component. It was discovered that the component is a polysaccharide with the following physical and chemical properties.
■ 元素分析値C:39%、H:7%、N:検出限界以
下
■分子l
約100〜500万の高分子物質
■ 呈色反応
12 クロモトロープ−硫酸反応 十il、アニリ
ンー塩酸反応
山、ナフトレゾルシノール反応
lv、カルバゾール−硫酸反応
V、エルソンーモルガン反応
■ 溶剤に対する溶解度
水に可溶、メタノール、エタノール、ア七トン、エーテ
ルに不溶。■ Elemental analysis value C: 39%, H: 7%, N: Below detection limit ■Molecular liter: Approximately 1 million to 5 million polymer substances■ Color reaction 12 Chromotrope-sulfuric acid reaction 10 il, aniline-hydrochloric acid reaction mountain, naphtho Resorcinol reaction lv, carbazole-sulfuric acid reaction V, Elson-Morgan reaction ■ Solubility in solvents Soluble in water, insoluble in methanol, ethanol, aptane, and ether.
■ 塩基性、酸性、中性の別 本物質の水溶液は中性である。■Basic, acidic, neutral Aqueous solutions of this substance are neutral.
■ 構成糖の種類及び組成比 グルコース:ガラクトース=1:1 ■外 観 無味無臭の白色粉末 ■ 紫外線吸収スペクトル 特性吸収を示さない。■ Types and composition ratio of constituent sugars Glucose:galactose=1:1 ■Exterior appearance Tasteless and odorless white powder ■ Ultraviolet absorption spectrum Does not exhibit characteristic absorption.
■ 赤外吸収スペクトル 第1図の通りの特性吸収を示す。■ Infrared absorption spectrum It shows characteristic absorption as shown in Figure 1.
本発明の有効成分を生産するラクトバチルスsp、 K
PB−167は、ケフィール粒から分離されるラクトバ
チルス属に属する長桿菌の一種で、その菌学的性質は次
の通りである。Lactobacillus sp, K which produces the active ingredient of the present invention
PB-167 is a type of long bacillus belonging to the genus Lactobacillus that is isolated from kefir grains, and its mycological properties are as follows.
A、菌の形態
(+) 細胞の大きさ: 1〜1,5x15〜60(
μm)(2)形 状:桿 状
(3)運 動 性:な し
く4)胞子の有We:な し
(5)ダラム染色:陽 性
蒸留水
00mJ2
B、培地に於ける生育状態
ミルクホエー寒天培地に菌を塗抹し、30℃で1週間嫌
気培養(ガスバック法又はグローブボックス法)した時
のコロニーの形態
培地組成
ミルクホエー
ラ り ト − ス
カザミノ酸
L−システィン塩酸塩
酢酸ナトリウム
ツイーン80**
ミネラルB…
寒 天
pI(
00mfi
1g
0.5g
o、 os g
O,5g
0.1g
mfi
1g
5.5
*ネ
本本本
10%脱脂乳を乳酸でpH4,6とし、30分煮沸後、
沈澱を濾別した濾液。A, Bacterial morphology (+) Cell size: 1-1,5x15-60 (
μm) (2) Shape: Rod-shaped (3) Motility: None 4) Spore presence: None (5) Durham staining: Positive Distilled water 00mJ2 B, Growth status in medium Milk whey agar medium Morphology of colonies when bacteria were smeared on the surface and cultured anaerobically at 30°C for one week (gas bag method or glove box method).Medium composition. Agar pI (00mfi 1g 0.5g o, os g O,5g 0.1g mfi 1g 5.5 *Nemotomoto 10% skim milk was adjusted to pH 4.6 with lactic acid, and after boiling for 30 minutes,
Filtrate after filtering out the precipitate.
ポリオキシエチレンソルビタンモ
ノオレートの商品名
組成: MgSO4・7H204g
MoSO4・4H200,Is g
FeSO4・7H200,18g
NaCl 0.1g
コロニーの性状
形状二円 形 色調:白色
大きさ:2〜4m 透明度:半透明隆起:凸円状
硬度:粘稠
周 縁:円 滑 構 造:均質、露滴状表面二円
滑
C9生理学的性質
■ 生育温度=30℃(至適)、20〜35℃(生育範
囲)
■ 生育p)1:5,5〜6(至適)、5〜7.5(生
育範囲)
■ 酸素に対する態度:通気嫌気性、好気下でも生育す
るが、C02存在下の方が生育良好。Trade name of polyoxyethylene sorbitan monooleate Composition: MgSO4・7H204g MoSO4・4H200, Is g FeSO4・7H200, 18g NaCl 0.1g Colony properties Shape 2 circles Shape Color tone: White Size: 2-4 m Transparency: Transparent ridges : Convex circular shape
Hardness: viscous periphery Edge: smooth Structure: homogeneous, dewdrop-like surface bi-smooth C9 Physiological properties ■ Growth temperature = 30℃ (optimal), 20-35℃ (growth range) ■ Growth p) 1: 5.5-6 (optimal), 5-7.5 (growth range) ■ Attitude towards oxygen: Aerobic anaerobic, grows even under aerobic conditions, but grows better in the presence of CO2.
■ 色素の生I&:なし
■ カタラーゼ:陰性
■ 糖からの生成乳酸の旋光性: D(L)型■ 糖類
からの酸及びガスの生成:
D(−)−アラビノース
D(+)−キシロース
α−L−ラムノース
D−リボース
グルコース
D−マンノース
D(−)−フラクトース
D−ガラクトース
シュクロース
マルトース
セロビオース
ラ り ト − ス
トレハロース
メルビオース
ラフィノース
メレチトース
D−マンニトール
D−ソルビトール
エ ス り リ ン
サ リ シ ン
アミクダリン
酸の生成
+
ガスの生成
この菌を用いて本発明の有効成分を生産するには、例え
ばミルクホエー培地又は修正MRS培地(第1表で示す
)で培養した後、培養液の上澄画分及び菌体表面画分か
ら通常の分離、採取方法によって行うことができる。■ Pigment production I &: None ■ Catalase: Negative ■ Optical rotation of lactic acid produced from sugar: D (L) type ■ Production of acid and gas from sugar: D (-) - Arabinose D (+) - Xylose α - L-rhamnose D-ribose glucose D-mannose D(-)-fructose D-galactose sucrose maltose cellobiose slurry - strehalose melbiose raffinose meletitose D-mannitol D-sorbitol ester Rin salicin amicdalic acid + Gas production To use this bacterium to produce the active ingredient of the present invention, for example, after culturing in milk whey medium or modified MRS medium (shown in Table 1), the supernatant fraction of the culture solution and the bacterium It can be carried out by conventional separation and collection methods from body surface fractions.
ミルクホエー培地及び修正MR5培地組成の例を第1表
に示すが、これに限られるものではない。また、培養条
件としては、温度25〜35℃、pl(4,5〜6,0
が好ましく、菌を接種して気相部をC02ガスで置換後
1M&気的条件下で培養するのが有利である。通常4〜
6日間培養すると、培養液中に本発明の有効成分である
多糖が蓄積する。Examples of milk whey medium and modified MR5 medium compositions are shown in Table 1, but are not limited thereto. In addition, the culture conditions include a temperature of 25 to 35°C, a pl (4,5 to 6,0
It is preferable to inoculate the bacteria, replace the gas phase with CO2 gas, and then culture under 1M&gas conditions. Usually 4~
When cultured for 6 days, polysaccharide, which is the active ingredient of the present invention, accumulates in the culture solution.
(以下余白)
第1表(培地組成)
注)本:上記のミルクホエーは10%脱脂粉乳を塩酸で
pH4,6とし、30分煮沸後濾過して得た濾液をNa
OHでpHを6.8とし、さらに30分煮沸濾過して得
た濾液である。(Margins below) Table 1 (Medium composition) Note: The above milk whey is made by adjusting 10% skim milk powder to pH 4.6 with hydrochloric acid, boiling it for 30 minutes, filtering it, and adding Na.
This is a filtrate obtained by adjusting the pH to 6.8 with OH and boiling and filtering for an additional 30 minutes.
以上のようにして得られたラクトバチルスsp、 KP
B−167を培養液中より本発明の有効成分を分離、精
製するには、培養液を10.00Orpm。Lactobacillus sp, KP obtained as above
To separate and purify the active ingredient of the present invention from the culture solution of B-167, the culture solution is heated at 10.00 rpm.
IO分間遠心分離して培養液上澄画分と菌体面分に分け
る。Centrifuge for IO minutes and separate into culture supernatant fraction and bacterial cell surface fraction.
上澄液画分に同量の有機溶媒(メタノール、エタノール
、アセトン等)好適には冷エタノールを添加して氷水中
で15分間静置後、遠心分離して沈澱した多糖を集める
。これを適量の蒸留水に溶解し、再度エタノールを加え
て多糖を再沈澱させ集める。この操作を数回繰返すこと
により多糖の精製を行なう。The same amount of an organic solvent (methanol, ethanol, acetone, etc.), preferably cold ethanol, is added to the supernatant fraction, and after standing in ice water for 15 minutes, the precipitated polysaccharide is collected by centrifugation. Dissolve this in an appropriate amount of distilled water, add ethanol again to reprecipitate the polysaccharide, and collect. The polysaccharide is purified by repeating this operation several times.
菌体画分中の多糖は、培養液を遠心分離して得られる菌
体を95℃の熱水中で30分熱抽出した後、再度遠心分
離して多糖の溶解している上澄液を得る。次いで、同量
の冷エタノール等の有機溶媒を加えて、前述の上澄液か
らの多糖の精製と同様の方法により数回の再沈澱によっ
て精製する。The polysaccharide in the bacterial cell fraction was obtained by centrifuging the culture solution, heat-extracting the bacterial cells in hot water at 95°C for 30 minutes, and centrifuging again to remove the supernatant in which the polysaccharides were dissolved. obtain. Next, the same amount of an organic solvent such as cold ethanol is added, and the polysaccharide is purified by reprecipitation several times in the same manner as for purifying the polysaccharide from the supernatant liquid described above.
以上の如くして得られた、ラクトバチルスsp、 KP
B−167の培養液中の多糖は分離精製され純粋な多糖
である。Lactobacillus sp, KP obtained as above
The polysaccharide in the culture solution of B-167 is separated and purified and is a pure polysaccharide.
この多糖は次の理化学的性質を有する。This polysaccharide has the following physical and chemical properties.
■ 元素分析値
C:39%、H:7%、N:検出限界以下■ 分子量
Asahipak G5−710 (旭化成■製〕カ
ラムを用いて、展開溶媒として蒸留水を用い、流速1.
0mfi/mnでのゲル濾過分析法によって、約100
〜500万であった。■ Elemental analysis values C: 39%, H: 7%, N: below the detection limit ■ Molecular weight Asahipak G5-710 (manufactured by Asahi Kasei ■) column was used, distilled water was used as the developing solvent, and the flow rate was 1.
By gel filtration analysis at 0 mfi/mn, approximately 100
It was ~5 million.
■ 呈色反応
1、クロモトロープ−硫酸反応 十
ii 、 アニリン−塩酸反応
山、ナフトレゾルシノール反応
lv、カルバゾール−硫酸反応
V、エルソンーモルガン反応
■ 溶媒に対する溶解度
水に可溶、メタノール、エタノール、アセトン、エーテ
ルに不溶。■ Color reaction 1, chromotrope-sulfuric acid reaction 11 ii, aniline-hydrochloric acid reaction mountain, naphtresorcinol reaction lv, carbazole-sulfuric acid reaction V, Elson-Morgan reaction ■ Solubility in solvents Soluble in water, methanol, ethanol, acetone, Insoluble in ether.
■ 塩基性、酸性、中性の別 本物質の水溶液は中性である。■Basic, acidic, neutral Aqueous solutions of this substance are neutral.
■ 構成糖の種類及び組成比
多糖を2N−トリプルオロ酢酸を用いて100℃で3時
間加水分解した後、分解溶液を減圧濃縮器で蒸発乾固し
て蒸留水に溶かし、液体クロマトグラフィーによる分析
を行った。使用カラムは5UGARSP−+010 C
昭和電工■製〕で、展開溶媒は蒸留水、流速0.7mQ
/min、温度80℃で分析した。その結果、グルコー
スとガラクトースからのみ構成され、その組成比は、グ
ルコース:ガラクトース=1.1であった。■ Types and composition ratio of constituent sugars After hydrolyzing polysaccharides with 2N-trioleoacetic acid at 100°C for 3 hours, the decomposed solution was evaporated to dryness in a vacuum concentrator, dissolved in distilled water, and analyzed by liquid chromatography. I did it. The column used is 5UGARSP-+010C
[manufactured by Showa Denko], the developing solvent was distilled water, flow rate 0.7 mQ.
/min at a temperature of 80°C. As a result, it was found that it was composed only of glucose and galactose, and the composition ratio was glucose:galactose=1.1.
■外 観 無味無臭の白色粉末。■Exterior appearance Tasteless and odorless white powder.
■ 紫外部吸収スペクトル 特性吸収を示さない。■ Ultraviolet absorption spectrum Does not exhibit characteristic absorption.
■ 赤外部吸収スペクトル 第1図の通りの特性吸収を示す。■ Infrared absorption spectrum It shows characteristic absorption as shown in Figure 1.
上記のラクトバチルスsp、 KPB−167を培養し
、分離精製した多糖の生理活性特に抗腫瘍活性並びに免
疫賦活性は次の通りである。The physiological activities, particularly the antitumor activity and immunostimulatory activity of the polysaccharide isolated and purified by culturing the Lactobacillus sp, KPB-167 described above, are as follows.
(1) 抗腫瘍活性
生後5週令、体重約30gのICR系マウス(オス)を
用い、−群8匹で試験した。予めICR系マウス(オス
)で10日日日に移植、継代しているザルコーマ180
(Sarcoma [10)細胞を、滅菌生理食塩水
で1 x107cells/1rillとなるように希
釈後、マウスの右足大腿部皮下に0.1−移植し、翌日
より生理食塩水に溶解した本発明の有効成分の多糖0.
25−を7日間腹腔内に連続投与した。対照には生理食
塩水のみを投与した。(1) Antitumor activity A test was conducted using 8 ICR mice (male) aged 5 weeks and weighing approximately 30 g in - group. Sarcoma 180, which has been transplanted and subcultured in ICR mice (male) for 10 days in advance.
(Sarcoma [10) cells were diluted with sterile physiological saline to 1 x 10 cells/1 rill, and then transplanted subcutaneously into the right thigh of a mouse, and from the next day, the cells of the present invention dissolved in physiological saline were Active ingredient polysaccharide 0.
25- was continuously administered intraperitoneally for 7 days. Controls received only physiological saline.
ザルコーマ180を移植後、毎日腫瘍の長径と短径をノ
ギスで計測し、腫瘍移植後300日目腫瘍抑制率を求め
た。After transplanting Sarcoma 180, the major and minor axes of the tumor were measured every day using calipers to determine the tumor suppression rate 300 days after tumor implantation.
腫瘍阻止率は下式により計算した。The tumor inhibition rate was calculated using the following formula.
o−S
腫瘍抑制率(%)= X100式中、Sは本発
明の有効成分の多糖
を投与した群の腫瘍の大きさ
(長径×短径)、SOは対照群
の腫瘍の大きさ(長径×短径)
結果は第2表の通りである。o-S Tumor suppression rate (%) = x short axis) The results are shown in Table 2.
第 2 表
以上のように本発明の有効成分である多糖は顕著に腫瘍
を抑制するものである。As shown in Table 2, the polysaccharide that is the active ingredient of the present invention significantly suppresses tumors.
(2)免疫賦活効果
生後6週令、体重約30gのICR系マウス(オス)を
用い、−群6匹を廟いて、本発明の有効成分である多糖
を投与してマウス膵臓中の羊赤血球に対する抗体産生細
胞数の増減を調べた。抗原としての羊赤血球4x109
Ce1ls/mfiをマウス腹腔内に0.25mfi
投与し、投与口をDay Oとした。DayOを基準と
し、基準日より前のDay−3,−2,−1の3日間、
多糖溶液0.25+nfiをマウス腹腔内に投与する。(2) Immunostimulatory effect Using ICR mice (male), 6 weeks old and weighing approximately 30 g, 6 mice in the - group were taken, and the polysaccharide, which is the active ingredient of the present invention, was administered to induce sheep red blood cells in the mouse pancreas. We investigated the increase or decrease in the number of antibody-producing cells. Sheep red blood cells 4x109 as antigen
Inject 0.25 mfi of Ce1ls/mfi into the mouse peritoneal cavity.
The administration port was designated as Day O. Based on Day O, the three days before the reference date, Day-3, -2, -1,
Polysaccharide solution 0.25+nfi is administered intraperitoneally to mice.
「前投与群」、基準日より後のDay+1.+2.+3
に投与する「後投与群」及び基準日より前のDay−3
,71と後の+1.+3に投与する「前後投与群」の3
群に分けた。対照としてはDay−3,−1゜+1.+
3に生理食塩水を0.25mA投与して「対照群」とし
た。なお、多糖溶液の濃度は全て40■/ kg /
d a yとした。"Pre-administration group", Day+1 after the reference date. +2. +3
"Post-administration group" administered on Day-3 before the reference date
, 71 and later +1. 3 of the “before and after administration group” administered at +3
divided into groups. As a control, Day-3, -1°+1. +
3, physiological saline was administered at 0.25 mA to form a "control group". In addition, the concentration of all polysaccharide solutions is 40■/kg/
d ay.
羊赤血球を投与後、6日目に全マウスを解剖してjp!
!taを抽出し、膵臓中の抗羊赤血球抗体産生細胞数を
カニンガム法で測定した。その結果を第3表に示す。All mice were dissected on the 6th day after administration of sheep red blood cells.
! ta was extracted, and the number of anti-sheep erythrocyte antibody-producing cells in the pancreas was measured by the Cunningham method. The results are shown in Table 3.
(以下余白)
第3表
以上のように本発明の有効成分である多糖は対照群に比
べて顕著にn*細胞当りの抗羊赤血球抗体産生細胞数が
増大している。(Margin below) As shown in Table 3 and above, the polysaccharide which is the active ingredient of the present invention significantly increases the number of anti-sheep erythrocyte antibody producing cells per n* cell compared to the control group.
この結果より、本発明の有効成分は免疫賦活効果が優れ
ていることが明らかである。From this result, it is clear that the active ingredient of the present invention has an excellent immunostimulatory effect.
(3) 急性毒性
生後5〜6週令、体重約30gのICR系マウス(オス
)を用いて、各試験群4匹に対し、本発明の多糖を1回
腹腔内投与及び経口投与してその急性毒性試験を行った
。(3) Acute Toxicity Using ICR mice (male) aged 5 to 6 weeks old and weighing approximately 30 g, the polysaccharide of the present invention was administered intraperitoneally and orally once to each test group of 4 mice. Acute toxicity tests were conducted.
投与後、3週間にわたって各試験群マウスの一般的症状
、死亡例について観察した。After administration, the mice in each test group were observed for general symptoms and mortality for 3 weeks.
その結果、腹腔的投与では試験群の最大濃度100■/
kg−マウスにおいて、何ら異常なく、また径口投与に
おいても試験群の最大濃度1500■/kg−マウスに
おいて何ら異常も見られなかった。従って、本発明の有
効成分である多糖は極めて安全性の高い物質であること
が郭fる。As a result, the maximum concentration in the test group was 100 μ/cm after intraperitoneal administration.
No abnormalities were observed in the test group mice at the maximum concentration of 1500 μg/kg mice after oral administration. Therefore, it can be concluded that the polysaccharide which is the active ingredient of the present invention is an extremely safe substance.
本発明の抗腫瘍剤、免疫賦活剤は、その症状、年令等に
より異なるが抗腫瘍剤の場合は1 mg 〜100mg
/kg/daL免疫賦活剤の場合は1 mg −100
mg/kg/dayを経口剤例えば錠剤、カプセル剤、
液剤等非経口剤例えば注射剤等に一般の製剤用助剤を用
い通常の製剤方法によって製剤とする。The antitumor agent and immunostimulant of the present invention vary depending on the symptoms, age, etc., but in the case of an antitumor agent, the amount is 1 mg to 100 mg.
/kg/daL for immunostimulants: 1 mg −100
mg/kg/day for oral preparations such as tablets, capsules,
Parenteral preparations such as liquid preparations, such as injection preparations, are prepared using common formulation auxiliaries and conventional preparation methods.
次に本発明の実施例を挙げる。Next, examples of the present invention will be described.
例1 有効成分の製造
トリプトン10gIQ、肉エキス10 g / Q、酵
母エキス5 gIQ、ラクトース20 g / Q、K
2HP0.2 g / Q、クエン酸ニアンモニウム2
gIQ、ツイーン801gIQ、酢酸ナトリウム5 g
/ Q 、 vgso4・7I(200,511g/Q
、 MnSO4・4H200,28g/ Qの修正M
R5培地200mfiをねじ口頚に入れ、ラクトバチル
スsp、 KPB−167菌株をこれに接種して気相部
をCO2ガスで置換し、後30℃で4日間嫌気的条件下
で静置培養を行い、前培養液とした。Example 1 Production of active ingredients Tryptone 10 g IQ, meat extract 10 g/Q, yeast extract 5 g IQ, lactose 20 g/Q, K
2HP0.2 g/Q, 2 ammonium citrate
gIQ, Tween 801gIQ, sodium acetate 5g
/ Q, vgso4・7I (200,511g/Q
, MnSO4・4H200,28g/Modified M of Q
Put 200 mfi of R5 medium into a screw cap neck, inoculate it with Lactobacillus sp, KPB-167 strain, replace the gas phase with CO2 gas, and then statically culture at 30°C for 4 days under anaerobic conditions. , was used as the preculture solution.
本培養はトリプトン20 g / Q、肉エキス20g
/Q、酵母エキス10g/Q、ラクトース100gIQ
、 K2HP0.2 gIQ、クエン酸ニアンモニウム
2gIQ、ツイー
ン801g/Q、酢酸ナトリウム5 gIQ、MgSO
4−7H200,58g/Q 、 MnSO4・4H2
00、28g / Q及び塩化カルシウム0.555
g /Qのケフィラン生産用MRS培地1.5Qを入れ
たカルチャーフラスコに、30trr(lの前培養液を
加え、気相部をCO2ガスで置換後、30℃、pus、
0制御下で培養を行った。培養中、乳酸の生成によりp
Hが低下するため、5N−苛性ソーダを滴下しpHを制
御し、攪拌はマグネチツクスターラーを用いて行った。Main culture is tryptone 20g/Q, meat extract 20g
/Q, yeast extract 10g/Q, lactose 100gIQ
, K2HP0.2 gIQ, ammonium citrate 2gIQ, Tween 801g/Q, sodium acetate 5gIQ, MgSO
4-7H200, 58g/Q, MnSO4・4H2
00, 28g/Q and calcium chloride 0.555
Add 30 trr (l) of preculture solution to a culture flask containing 1.5 Q of MRS medium for producing kefiran at g/Q, and after replacing the gas phase with CO2 gas, heat at 30°C, pus,
Culture was performed under 0 control. During culture, p due to the production of lactic acid.
Since H was lowered, 5N caustic soda was added dropwise to control the pH, and stirring was performed using a magnetic stirrer.
6日間培養した後、培養液上澄中から
多糖を回収した6即ち、培養液IQを
10.00Orpm、 15分間遠心分離して、培養液
上澄画分と菌体画分に分けた。培養液上澄画分からの多
糖の回収は、上澄液に同量(IQ)の冷エタノール(9
9,5%)を添加して氷水中で15分間静置後、
10、00Orpm、15分間遠心分離して、沈澱部に
多糖を得た。得られた多糖を500rnflの蒸留水に
溶解した後、更に500mQの冷エタノール(99,5
%)を添加して氷水中で静置し、多糖を沈澱させた。こ
のエタノール沈澱操作を3回繰り返して行い多糖の精製
を行い、後凍結乾燥して多糖の白色粉末1.97gを得
た。After culturing for 6 days, the polysaccharides were recovered from the culture supernatant. 6 That is, the culture solution IQ was centrifuged at 10.00 rpm for 15 minutes and separated into a culture supernatant fraction and a bacterial cell fraction. Polysaccharides can be recovered from the culture supernatant fraction by adding the same amount (IQ) of cold ethanol (9
After adding 9.5%) and standing in ice water for 15 minutes, the mixture was centrifuged at 10.00 rpm for 15 minutes to obtain a polysaccharide in the precipitate. After dissolving the obtained polysaccharide in 500rnfl of distilled water, further 500mQ of cold ethanol (99,5
%) and allowed to stand in ice water to precipitate the polysaccharide. This ethanol precipitation operation was repeated three times to purify the polysaccharide, which was then freeze-dried to obtain 1.97 g of a white polysaccharide powder.
例2 錠 剤
(1) 例1で得られた多糖 20g乳糖
100g
結晶セルロース 30g
馬鈴薯澱粉 30g
ステアリン酸マグネシウム 2g
(1)〜(4)の成分を混合し、予め別けておいた(4
)の一部を糊として添加し顆粒とし、乾燥する。これに
(5)を加え混合して、1 g200■の錠剤とする。Example 2 Tablet (1) Polysaccharide obtained in Example 1 20g lactose
100g Crystalline cellulose 30g Potato starch 30g Magnesium stearate 2g Mix the ingredients (1) to (4) and separate them in advance (4
) is added as a glue, made into granules, and dried. Add (5) to this and mix to make 1 g 200 square tablets.
例3 カプセル剤
(1) 例1で得られた多糖 20g(2)
乳糖 100g
(3) 結晶セルロース 50g(4)
タルク 10g以上の(1
)〜(4)を混合し、200■ずつカプセルに充填する
。Example 3 Capsule (1) Polysaccharide obtained in Example 1 20g (2)
Lactose 100g (3) Crystalline cellulose 50g (4)
Talc 10g or more (1
) to (4) were mixed and filled into 200 square capsules.
本発明は優れた抗腫瘍活性並びに免疫賦活効果を有する
抗腫瘍、免疫賦活剤である。そして、毒性が極めて低く
安全にヒトに投与す4゜
ることができる有用な薬剤である。The present invention is an antitumor and immunostimulant having excellent antitumor activity and immunostimulatory effect. Furthermore, it is a useful drug with extremely low toxicity and can be safely administered to humans.
第1図は本発明の有効成分である多糖の赤外吸収スペク
トルである。
密 噸 緩 IFIG. 1 shows an infrared absorption spectrum of polysaccharide, which is an active ingredient of the present invention. Dense Speech Loose I
Claims (1)
第9886号)を培養し、その培養液から分離、採取さ
れた多糖を有効成分とする抗腫瘍、免疫賦活剤。 2、多糖が次の理化学的性質を有する抗腫瘍、免疫賦活
剤。 (1)元素分析値C:39%、H:7%、N:検出限界
以下 (2)分子量約100〜500万の高分子物質 (3)呈色反応 i、クロモトロープ−硫酸反応 + ii、アニリン−塩酸反応 − iii、ナフトレゾルシノール反応 − iv、カルバゾール−硫酸反応 − v、エルソン−モルガン反応 − (4)溶剤に対する溶解度水に可溶、メタノール、エタ
ノール、アセトン、エーテルに不溶。 (5)塩基性、酸性、中性の別本物質の水溶液は中性で
ある。 (6)構成糖の種類及び組成比グルコース:ガラクトー
ス=1:1 (7)外観無味無臭の白色粉末 (8)紫外部吸収スペクトル特性吸収を示さない。 (9)赤外部吸収スペクトル第1図の通りの特性吸収を
示す。[Claims] 1. Lactobacillus sp. An anti-tumor and immunostimulant containing a polysaccharide isolated and collected from the culture solution obtained by culturing KPB-167 (KPB-167 (Feikoken Bacteria No. 9886)) as an active ingredient. 2. Antitumor and immunostimulant whose polysaccharide has the following physical and chemical properties. (1) Elemental analysis value C: 39%, H: 7%, N: below the detection limit (2) High molecular weight substance with a molecular weight of approximately 1 million to 5 million (3) Color reaction i, chromotrope-sulfuric acid reaction + ii, Aniline-hydrochloric acid reaction - iii, naphresorcinol reaction - iv, carbazole-sulfuric acid reaction - v, Elson-Morgan reaction - (4) Solubility in solvents Soluble in water, insoluble in methanol, ethanol, acetone, and ether. (5) Basic, acidic, and neutral Aqueous solutions of this substance are neutral. (6) Types of constituent sugars and composition ratio glucose:galactose = 1:1 (7) Appearance: Tasteless and odorless white powder (8) Ultraviolet absorption spectrum characteristics: Shows no absorption. (9) Infrared absorption spectrum Shows characteristic absorption as shown in Figure 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2094377A JPH03291232A (en) | 1990-04-09 | 1990-04-09 | Antitumor agent and immunoactivator |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2094377A JPH03291232A (en) | 1990-04-09 | 1990-04-09 | Antitumor agent and immunoactivator |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH03291232A true JPH03291232A (en) | 1991-12-20 |
Family
ID=14108630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2094377A Pending JPH03291232A (en) | 1990-04-09 | 1990-04-09 | Antitumor agent and immunoactivator |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH03291232A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424201A (en) * | 1990-05-31 | 1995-06-13 | Sapporo Breweries Limited | Method for preparing an antitumor dextran using Lactobacillus confusus |
-
1990
- 1990-04-09 JP JP2094377A patent/JPH03291232A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424201A (en) * | 1990-05-31 | 1995-06-13 | Sapporo Breweries Limited | Method for preparing an antitumor dextran using Lactobacillus confusus |
US5484715A (en) * | 1990-05-31 | 1996-01-16 | Sapporo Breweries Limited | Method for preparing an antitumor dextran using a dextran synthetase from Lactobacillus confusus |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4229440A (en) | Pharmaceutical composition containing the polysaccharide KGF-C as active ingredient | |
JPH021154B2 (en) | ||
EP0459367A1 (en) | Method for preparing an antitumor dextran | |
US4209507A (en) | Novel anti-tumor substance and preparation thereof | |
JP4390259B2 (en) | Sulfuric acid polysaccharide, method for producing the same, and substance containing the same as an active ingredient | |
JPH03291232A (en) | Antitumor agent and immunoactivator | |
US6727081B2 (en) | Microorganism isolated from chinese elm (Ulmus sp.) and process for preparing exopolysaccharides by employing the microorganism | |
EP0067000B1 (en) | Production of a nitrogen-containing polysaccharide having antitumour activity | |
US4016260A (en) | Novel polypeptide produced by pseudomonas | |
FI79140B (en) | FOERFARANDE FOER FRAMSTAELLNING AV ETT TF-500-AEMNE MED KARSINOSTATISK OCH IMMUNITET STIMULERANDE AKTIVITET. | |
KR890002256B1 (en) | Process for preparing anticanser tf-2 | |
JPS627916B2 (en) | ||
EP0053800B1 (en) | Heteroglycan, process for the production of same, and immunological activator containing same | |
JPS627918B2 (en) | ||
JPH0223864A (en) | Lactobacillus sp.kpb-167 and production of mucopolysaccharides by said lactobacillus | |
NO157426B (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE COMPOUNDS FOR THE CULTIVATION OF MICRO-ORGANISMS. | |
NO155697B (en) | PROCEDURE FOR THE PREPARATION OF PHYSIOLOGICALLY ACTIVE COMPOUNDS. | |
JPH0242478B2 (en) | ||
JPS58121798A (en) | Polysaccharide mp-67 and its production | |
JPS61225125A (en) | Antitumor agent | |
DK165641B (en) | Process for preparing TF-220, TF-230 and TF-240 compounds, and the corresponding protein-free compounds | |
CA2009194A1 (en) | Method for producing biologically active polysaccharide ron substance | |
JPS6261036B2 (en) | ||
JPH0460632B2 (en) | ||
JPH01191694A (en) | Substance having antitumor activity |